Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT03770702
Recruiting Phase 3

Statins and ARBs on Rheumatoid Activity

NCT03770702 · tracked via the Priya Life Science Egypt tracker
Sponsor
Sherief Abd-Elsalam
Phase
Phase 3
Started
2018-10-01
Last updated
2018-12-10

Condition(s) studied

Rheumatoid Arthritis

Investigational drug(s) / intervention(s)

Angiotensin receptor blockersStatins

Angiotensin receptor blockers: Candesartan

Statins: Atorvastatin

Study summary

Investigational and comparative study between the anti-inflammatory effectof both angiotensin reeptor blockers and statins on rheumatoid arthritis disease activity on Egyptian patients

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Rheumatoid arthritis. Exclusion Criteria: * Pregnant or lactating * Hepatic or renal impairment.

Primary outcome measure(s)

  • Change in disease activity score — 6 months
    DAS28-ESR

Trial sites (1)

FacilityCityRegionStatus
Sherief Abd-Elsalam Tanta Egypt Recruiting

More Sherief Abd-Elsalam trials in Egypt

Role of Point of Care Ultrasound in Endotracheal Tube Placement Recruiting
Effect of Some Drugs on Rheumatoid Arithritis Activity Recruiting
Effect of Some Drugs on Liver Fibrosis Recruiting
Role of Bumetanide in Treatment of Autism Recruiting
Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis Recruiting

Other trials for the same condition

Desloratadine as Adjunct Therapy for Rheumatoid Arthritis Recruiting
The Effect of Nicotinamide on the Clinical Outcome of Rheumatoid Arthritis Patients Recruiting
Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis Recruiting
Baricitinib Effects on Procoagulant State in Rheumatoid Arthritis Starting soon
Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhibitor Baricitinib Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03770702 on ClinicalTrials.gov ↗ ← All trials in Egypt